Clinical trials
Rectal Cancer, Radiotherapy clinical trials
Below are recruiting rectal cancer, radiotherapy clinical trials, each written for real people, not researchers. We’re tracking 206 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07686640RecruitingPhase 3
Short course radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Jinan, ShandongAges 18–75 - NCT03573791Recruiting
Testing markers to predict chemo-radiation response in rectal cancer
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
Wuhan, HubeiAges 18–75 - NCT07162714RecruitingPhase 2
Short-course radiation plus AK112 for mismatch repair-proficient rectal cancer
This trial tests a new immunotherapy drug (AK112) given after a short course of radiation. It is for people with a specific type of mid-low rectal cancer that has not spread and has not been treated before.
Hangzhou, ZhejiangAges 18–75 - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06462053RecruitingPhase 2
Short radiotherapy plus chemo and immunotherapy for early low rectal cancer
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
ShanghaiAges 18–75 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT05972655RecruitingPhase 2
Testing shorter rectal radiation with chemotherapy plus immunotherapy
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hanzhou, ZhejiangAges 18–75 - NCT05378919RecruitingPhase 2
Testing new pre-surgery treatment for locally advanced rectal cancer
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
KaunasAges 18 years+ - NCT05555888RecruitingPhase 2
Immunotherapy plus short-course radiation for early rectal cancer
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07281157RecruitingPhase 2
Liposomal irinotecan, capecitabine and enlonstobart with short radiation for rectal cancer
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07183865RecruitingPhase 2
Radiation, chemo, and immunotherapy for recurrent rectal cancer
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04695782RecruitingPhase 2
Proton radiation for recurrent rectal cancer in the pelvis
This trial studies “pencil beam” proton radiation for rectal cancer that has come back in the pelvis after you already had radiation. It aims to control the recurrence while trying to limit harm to nearby organs.
AarhusAges 18 years+ - NCT07150949RecruitingPhase 2
Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT07005570RecruitingPhase 2
Short radiation and chemo with or without immunotherapy for rectal cancer
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Guangzhou, GuangdongAges 18–75 - NCT05912075RecruitingPhase 1
New pre-surgery radiation plus ASTX660 for rectal cancer
This early-phase trial tests adding ASTX660 (a new drug) to pre-surgery radiation for locally advanced rectal cancer. It aims to improve control of the tumor before surgery, making it more likely that the surgeon can remove it with clear margins.
Lyon, RhöneAges 18 years+ - NCT07040098RecruitingPhase 2
Optimizing immunotherapy with chemo-radiation for rectal cancer
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
BeijingAges 18–75 - NCT06802172Recruiting
Timing meals during cancer treatment for Alaska Native patients
This study tests whether scheduling meals at specific times of day can improve how patients feel during cancer treatment. It is for Alaska Native or American Indian people with certain cancers (rectal, HER2+ or triple negative breast, or other solid tumors) who are receiving neoadjuvant (before surgery) or adjuvant (after surgery) therapy.
Anchorage, AlaskaAges 21 years+ - NCT04098471Recruiting
Comparing two rectal cancer surgeries for T2 tumors
This trial compares two different surgery approaches for early-stage rectal cancer (T2N0M0) that is close to the anus. It tests whether a less invasive local removal followed by radiation works as well as more extensive surgery (total mesorectal excision).
Nanjing, JiangsuAges 18–75 - NCT03466424Recruiting
Short radiation then chemotherapy for locally advanced rectal cancer
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
Fuzhou, FujianAges 18–70 - NCT03516708RecruitingPhase 1/Phase 2
Epacadostat with pre-op radiation for locally advanced rectal cancer
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Orange, CaliforniaAges 18 years+ - NCT03853733Recruiting
Shorter radiation plan for non-surgery rectal cancer
This trial looks at a shorter radiation schedule for people with advanced rectal (or nearby sigmoid) cancer who cannot have surgery. The goal is to control the cancer while keeping treatment simpler, especially for those who cannot safely undergo an operation.
Terrassa, CataloniaAges 18 years+
Hear when a new Rectal Cancer, Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rectal cancer, radiotherapy?
- Yes. Clin2 currently lists 206 recruiting rectal cancer, radiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rectal cancer, radiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rectal cancer, radiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.